Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Microglia across the lifespan: from origin to function in brain development, plasticity and cognition.
Neuroprotective effects of resident microglia following acute brain injury.
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Rituximab does not reset defective early B cell tolerance checkpoints.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Dimethylfumarate Impairs Neutrophil Functions.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Interleukin-1beta promotes repair of the CNS.
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Firategrast
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Multiple sclerosis: pathogenesis and treatment.

Pages